GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.23
−3.46%Nov 4, 2026, 12:00 UTC
Genprex announced research finding that low TROP2 expression was associated with resistance to its REQORSA gene therapy across multiple preclinical models of non-small cell lung cancer.
Source:Oct 28, 2026, 11:00 UTC
Genprex announced that research conducted under its sponsored collaboration with Meharry Medical College will be featured at the The Gerontological Society of America 2026 Annual Scientific Meeting on November 4–7, 2026.
Source:Oct 21, 2026, 11:00 UTC
Researchers at Meharry Medical College published a peer-reviewed mouse study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis and synaptic pathways during brain aging.
Source:Aug 18, 2026, 11:00 UTC
Genprex entered into a development and manufacturing agreement with a leading U.S.-based CDMO to scale up manufacturing of its diabetes gene therapy program, transitioning from research-grade to clinical and commercial-ready production.
Source:Aug 3, 2026, 11:00 UTC
Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer clinical trials.
Source: